Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05654623




Registration number
NCT05654623
Ethics application status
Date submitted
16/11/2022
Date registered
16/12/2022

Titles & IDs
Public title
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.
Scientific title
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)
Secondary ID [1] 0 0
2022-500544-38-00
Secondary ID [2] 0 0
C4891001
Universal Trial Number (UTN)
Trial acronym
VERITAC-2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ARV-471
Treatment: Drugs - Fulvestrant

Experimental: ARV-471 -

Active comparator: Fulvestrant -


Treatment: Drugs: ARV-471
orally, once daily on a 28-day continuous dosing schedule

Treatment: Drugs: Fulvestrant
intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS)
Timepoint [1] 0 0
From randomization date (every 8 weeks for the first 48 weeks and then every 12 weeks thereafter) to date of first documentation of progression OR death (approximately 2 years).
Secondary outcome [1] 0 0
Overall survival (OS)
Timepoint [1] 0 0
From randomization date (every 3 months) to date of death (approximately 3 years)
Secondary outcome [2] 0 0
Objective Response Rate (ORR)
Timepoint [2] 0 0
From randomization date (every 8 weeks during the first 48 weeks and then every 12 weeks) to the date of progression OR death (approximately to 2 years).
Secondary outcome [3] 0 0
Duration of response (DR)
Timepoint [3] 0 0
From the date of the first objective response (every 8 weeks during the first 48 weeks and then every 12 week) to the date of disease progression or death (approximately to 2 years).
Secondary outcome [4] 0 0
Clinical Benefit Rate
Timepoint [4] 0 0
From randomization date (every 8 weeks during the first 48 weeks and then every 12 weeks) to the date of progression or death (approximately to 2 years).
Secondary outcome [5] 0 0
Number of participants with treatment emergent adverse events (TEAEs), serious adverse events (SAEs), electrocardiogram (ECG) and laboratory abnormalities
Timepoint [5] 0 0
From screening until 28 days after the last dose (approximately 2 years).
Secondary outcome [6] 0 0
QT Interval (QTc)
Timepoint [6] 0 0
From baseline to end of treatment (approximately 2 years).
Secondary outcome [7] 0 0
Plasma Concentration Versus Time of ARV-471
Timepoint [7] 0 0
From randomization date up to cycle 7 (each cycle is 28 days).
Secondary outcome [8] 0 0
Health state utility and health status will be assessed using the European Quality of Life Group questionnaire with 5 dimensions and 5 levels per dimension (EQ-5D-5L)
Timepoint [8] 0 0
From screening and every cycle until cycle 6 (each cycle is 28 days), and then every other cycle until 28 days after the last dose (approximately 2 years).
Secondary outcome [9] 0 0
Disease-related Quality of Life will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30)
Timepoint [9] 0 0
From screening and every cycle until cycle 6 (each cycle is 28 days), and then every other cycle until 28 days after the last dose (approximately 2 years).
Secondary outcome [10] 0 0
Disease- and treatment-related Quality of Life will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) breast cancer module (QLQ-BR23) questionnaire
Timepoint [10] 0 0
From screening and every cycle until cycle 6 (each cycle is 28 days), and then every other cycle until 28 days after the last dose (approximately 2 years).
Secondary outcome [11] 0 0
Clinical Pain and its impact on functioning will be assessed using Brief Pain Inventory Short Form (BPI-SF) questionnaire.
Timepoint [11] 0 0
From screening and every cycle until cycle 6 (cycle=28 days) and then every other cycle until 28 days after the last dose (appr. 2 yrs).The modified BPI-SF (worst pain severity and pain interference) daily from baseline until the EOT (appr 2 yrs)
Secondary outcome [12] 0 0
circulating deoxyribonucleic acid (DNA)
Timepoint [12] 0 0
From baseline to end of treatment (approximately 2 years).

Eligibility
Key inclusion criteria
* Adult participants with loco-regional recurrent or metastatic breast disease not amenable to surgical resection or radiation therapy
* Confirmed diagnosis of ER+/HER2- breast cancer
* Prior therapies for locoregional recurrent or metastatic disease must fulfill all the following criteria:
* One line of CDK4/6 inhibitor therapy in combination with endocrine therapy. Only one line of CDK4/6 inhibitor is allowed in any setting.
* = 1 endocrine therapy in addition to CDK4/6 inhibitor with ET
* Most recent endocrine treatment duration must have been given for =6 months prior to disease progression. This may be the endocrine treatment component of the CDK4/6 inhibitor line of therapy.
* Radiological progression during or after the last line of therapy.
* Measurable disease evaluable per Response Evaluation Criterion in Solid Tumors (RECIST) v.1.1 or non-measurable bone-only disease
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Participants should be willing to provide blood and tumor tissue
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participants with advanced, symptomatic visceral spread, that are at risk of life-threatening complications in the short term
* Prior treatment with:
* ARV-471, fulvestrant, elacestrant, mTOR, PI3K, AKT pathway inhibitors, PARP inhibitor for any setting
* other investigational agents (including novel endocrine therapy any SERDs, SERCAs, CERANs) for any setting
* prior chemotherapy for advanced/metastatic disease
* Inadequate liver, kidney and bone marrow function
* Active brain metastases
* Participants with significant concomitant illness

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/03/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
15/05/2028
Actual
Sample size
Target
560
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,TAS,VIC
Recruitment hospital [1] 0 0
Sunshine Coast University Private Hospital - Birtinya
Recruitment hospital [2] 0 0
Icon Cancer Centre Hobart - Hobart
Recruitment hospital [3] 0 0
Cabrini Hospital -Brighton - Brighton
Recruitment hospital [4] 0 0
Barwon Health - Geelong
Recruitment hospital [5] 0 0
Cabrini Hospital - Malvern - Malvern
Recruitment postcode(s) [1] 0 0
4575 - Birtinya
Recruitment postcode(s) [2] 0 0
7000 - Hobart
Recruitment postcode(s) [3] 0 0
3186 - Brighton
Recruitment postcode(s) [4] 0 0
3220 - Geelong
Recruitment postcode(s) [5] 0 0
3144 - Malvern
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Kentucky
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Mississippi
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
Nevada
Country [9] 0 0
United States of America
State/province [9] 0 0
New Hampshire
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
Oklahoma
Country [13] 0 0
United States of America
State/province [13] 0 0
Oregon
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Virginia
Country [17] 0 0
United States of America
State/province [17] 0 0
West Virginia
Country [18] 0 0
Argentina
State/province [18] 0 0
Ciudad Autónoma DE Buenos Aires
Country [19] 0 0
Argentina
State/province [19] 0 0
Santa FE
Country [20] 0 0
Argentina
State/province [20] 0 0
Buenos Aires
Country [21] 0 0
Belgium
State/province [21] 0 0
Antwerpen
Country [22] 0 0
Belgium
State/province [22] 0 0
Bruxelles-capitale, Région DE
Country [23] 0 0
Belgium
State/province [23] 0 0
Hainaut
Country [24] 0 0
Belgium
State/province [24] 0 0
Vlaams-brabant
Country [25] 0 0
Brazil
State/province [25] 0 0
Espírito Santo
Country [26] 0 0
Brazil
State/province [26] 0 0
RIO Grande DO SUL
Country [27] 0 0
Brazil
State/province [27] 0 0
SÃO Paulo
Country [28] 0 0
Brazil
State/province [28] 0 0
São Paulo
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Burgas
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Gabrovo
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Haskovo
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Plovdiv
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Ruse
Country [34] 0 0
Bulgaria
State/province [34] 0 0
Vratsa
Country [35] 0 0
Canada
State/province [35] 0 0
Alberta
Country [36] 0 0
Canada
State/province [36] 0 0
British Columbia
Country [37] 0 0
Canada
State/province [37] 0 0
New Brunswick
Country [38] 0 0
Canada
State/province [38] 0 0
Ontario
Country [39] 0 0
Canada
State/province [39] 0 0
Quebec
Country [40] 0 0
China
State/province [40] 0 0
Anhui
Country [41] 0 0
China
State/province [41] 0 0
Fujian
Country [42] 0 0
China
State/province [42] 0 0
Guangdong
Country [43] 0 0
China
State/province [43] 0 0
Guangxi
Country [44] 0 0
China
State/province [44] 0 0
Hubei
Country [45] 0 0
China
State/province [45] 0 0
Jiangsu
Country [46] 0 0
China
State/province [46] 0 0
Jiangxi
Country [47] 0 0
China
State/province [47] 0 0
Jilin
Country [48] 0 0
China
State/province [48] 0 0
Liaoning
Country [49] 0 0
China
State/province [49] 0 0
Shaanxi/china
Country [50] 0 0
China
State/province [50] 0 0
Shaanxi
Country [51] 0 0
China
State/province [51] 0 0
Shandong
Country [52] 0 0
China
State/province [52] 0 0
Shanghai
Country [53] 0 0
China
State/province [53] 0 0
Yunnan
Country [54] 0 0
China
State/province [54] 0 0
Zhejiang
Country [55] 0 0
China
State/province [55] 0 0
Zhengzhou
Country [56] 0 0
Czechia
State/province [56] 0 0
Brno-mesto
Country [57] 0 0
Czechia
State/province [57] 0 0
Praha 4
Country [58] 0 0
Czechia
State/province [58] 0 0
Praha 8
Country [59] 0 0
Czechia
State/province [59] 0 0
Olomouc
Country [60] 0 0
Czechia
State/province [60] 0 0
Praha 10
Country [61] 0 0
Finland
State/province [61] 0 0
Pirkanmaa
Country [62] 0 0
Finland
State/province [62] 0 0
Pohjanmaa
Country [63] 0 0
Finland
State/province [63] 0 0
Pohjois-pohjanmaa
Country [64] 0 0
Finland
State/province [64] 0 0
Pori
Country [65] 0 0
France
State/province [65] 0 0
Côte-d'or
Country [66] 0 0
France
State/province [66] 0 0
Loire-atlantique
Country [67] 0 0
France
State/province [67] 0 0
Maine-et-loire
Country [68] 0 0
France
State/province [68] 0 0
Puy-de-dôme
Country [69] 0 0
France
State/province [69] 0 0
Vienne
Country [70] 0 0
France
State/province [70] 0 0
Île-de-france
Country [71] 0 0
Germany
State/province [71] 0 0
Baden-württemberg
Country [72] 0 0
Germany
State/province [72] 0 0
Mecklenburg-vorpommern
Country [73] 0 0
Germany
State/province [73] 0 0
Berlin
Country [74] 0 0
Greece
State/province [74] 0 0
Acha?a
Country [75] 0 0
Greece
State/province [75] 0 0
Attikí
Country [76] 0 0
Greece
State/province [76] 0 0
Irakleío
Country [77] 0 0
Greece
State/province [77] 0 0
Thessalía
Country [78] 0 0
Hungary
State/province [78] 0 0
Budapest
Country [79] 0 0
India
State/province [79] 0 0
Andhra Pradesh
Country [80] 0 0
India
State/province [80] 0 0
Delhi
Country [81] 0 0
India
State/province [81] 0 0
Haryana
Country [82] 0 0
India
State/province [82] 0 0
Maharashtra
Country [83] 0 0
India
State/province [83] 0 0
WEST Bengal
Country [84] 0 0
Israel
State/province [84] 0 0
Hamerkaz
Country [85] 0 0
Italy
State/province [85] 0 0
Campania
Country [86] 0 0
Italy
State/province [86] 0 0
Catania
Country [87] 0 0
Italy
State/province [87] 0 0
Emilia-romagna
Country [88] 0 0
Italy
State/province [88] 0 0
Lazio
Country [89] 0 0
Italy
State/province [89] 0 0
Lombardia
Country [90] 0 0
Italy
State/province [90] 0 0
Marche
Country [91] 0 0
Italy
State/province [91] 0 0
Toscana
Country [92] 0 0
Italy
State/province [92] 0 0
Macerata
Country [93] 0 0
Italy
State/province [93] 0 0
Milano
Country [94] 0 0
Italy
State/province [94] 0 0
Padova
Country [95] 0 0
Japan
State/province [95] 0 0
Aichi
Country [96] 0 0
Japan
State/province [96] 0 0
Chiba
Country [97] 0 0
Japan
State/province [97] 0 0
Hokkaido
Country [98] 0 0
Japan
State/province [98] 0 0
Kanagawa
Country [99] 0 0
Japan
State/province [99] 0 0
Osaka
Country [100] 0 0
Japan
State/province [100] 0 0
Saitama
Country [101] 0 0
Japan
State/province [101] 0 0
Tokyo
Country [102] 0 0
Japan
State/province [102] 0 0
Fukuoka
Country [103] 0 0
Japan
State/province [103] 0 0
Kagoshima
Country [104] 0 0
Japan
State/province [104] 0 0
Okayama
Country [105] 0 0
Korea, Republic of
State/province [105] 0 0
Incheon-gwangyeoksi [incheon]
Country [106] 0 0
Korea, Republic of
State/province [106] 0 0
Kyonggi-do
Country [107] 0 0
Korea, Republic of
State/province [107] 0 0
Seoul-teukbyeolsi [seoul]
Country [108] 0 0
Norway
State/province [108] 0 0
Akershus
Country [109] 0 0
Norway
State/province [109] 0 0
Buskerud
Country [110] 0 0
Poland
State/province [110] 0 0
Mazowieckie
Country [111] 0 0
Poland
State/province [111] 0 0
Malopolskie
Country [112] 0 0
Poland
State/province [112] 0 0
Podlaskie
Country [113] 0 0
Poland
State/province [113] 0 0
Pomorskie
Country [114] 0 0
Poland
State/province [114] 0 0
Lódzkie
Country [115] 0 0
Puerto Rico
State/province [115] 0 0
Hato Rey
Country [116] 0 0
Puerto Rico
State/province [116] 0 0
Rio Piedras
Country [117] 0 0
Puerto Rico
State/province [117] 0 0
San Juan
Country [118] 0 0
Slovakia
State/province [118] 0 0
Bratislava
Country [119] 0 0
Slovakia
State/province [119] 0 0
Kosice
Country [120] 0 0
Slovakia
State/province [120] 0 0
Michalovce
Country [121] 0 0
Slovakia
State/province [121] 0 0
Partizanske
Country [122] 0 0
Slovakia
State/province [122] 0 0
Presov
Country [123] 0 0
Slovakia
State/province [123] 0 0
Trnava
Country [124] 0 0
South Africa
State/province [124] 0 0
FREE State
Country [125] 0 0
South Africa
State/province [125] 0 0
Gauteng
Country [126] 0 0
South Africa
State/province [126] 0 0
Western CAPE
Country [127] 0 0
Spain
State/province [127] 0 0
A Coruña [LA Coruña]
Country [128] 0 0
Spain
State/province [128] 0 0
Alicante
Country [129] 0 0
Spain
State/province [129] 0 0
Barcelona [barcelona]
Country [130] 0 0
Spain
State/province [130] 0 0
Catalunya [cataluña]
Country [131] 0 0
Spain
State/province [131] 0 0
Gipuzkoa
Country [132] 0 0
Spain
State/province [132] 0 0
Lleida [lérida]
Country [133] 0 0
Spain
State/province [133] 0 0
Madrid, Comunidad DE
Country [134] 0 0
Spain
State/province [134] 0 0
Málaga
Country [135] 0 0
Spain
State/province [135] 0 0
PAÍS Vasco
Country [136] 0 0
Spain
State/province [136] 0 0
Granada
Country [137] 0 0
Spain
State/province [137] 0 0
Madrid
Country [138] 0 0
Spain
State/province [138] 0 0
Manresa
Country [139] 0 0
Sweden
State/province [139] 0 0
Stockholms LÄN [se-01]
Country [140] 0 0
Sweden
State/province [140] 0 0
Sundsvall
Country [141] 0 0
Switzerland
State/province [141] 0 0
Aargau
Country [142] 0 0
Switzerland
State/province [142] 0 0
Grisons
Country [143] 0 0
Switzerland
State/province [143] 0 0
Thurgau
Country [144] 0 0
Switzerland
State/province [144] 0 0
Ticino
Country [145] 0 0
Switzerland
State/province [145] 0 0
Winterthur
Country [146] 0 0
Taiwan
State/province [146] 0 0
Changhua
Country [147] 0 0
Taiwan
State/province [147] 0 0
Kaohsiung
Country [148] 0 0
Taiwan
State/province [148] 0 0
Tainan
Country [149] 0 0
Taiwan
State/province [149] 0 0
Taichung
Country [150] 0 0
Taiwan
State/province [150] 0 0
Taipei
Country [151] 0 0
Taiwan
State/province [151] 0 0
Taoyuan
Country [152] 0 0
Turkey
State/province [152] 0 0
I?stanbul
Country [153] 0 0
Turkey
State/province [153] 0 0
Adana
Country [154] 0 0
Turkey
State/province [154] 0 0
Ankara
Country [155] 0 0
Turkey
State/province [155] 0 0
Antalya
Country [156] 0 0
United Kingdom
State/province [156] 0 0
London, CITY OF
Country [157] 0 0
United Kingdom
State/province [157] 0 0
Oxfordshire
Country [158] 0 0
United Kingdom
State/province [158] 0 0
Blackburn

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Arvinas Estrogen Receptor, Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Country 0 0
Phone 0 0
1-800-718-1021
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT05654623